This document is currently under review:

For queries relating to this document please contact

 Updates to the hazardous drugs table:

Whilst eviQ strives to ensure the information in this document is up to date, we are awaiting the final publication of the NIOSH List of Hazardous Drugs in Healthcare Settings, 2020 which is still in draft form. Click here to view the draft list .

Updates to the current NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016 can be found here

This document reflects what is currently regarded as safe practice. While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference throughout the document to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information source. Use is subject to eviQ’s disclaimer available at

Send feedback for this page

First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

29 Feb 2024